Literature DB >> 15143964

Intraoperative radiotherapy during breast conserving surgery in patients previously treated with radiotherapy for Hodgkin's disease.

Mattia Intra1, Maria Cristina Leonardi, Giovanna Gatti, Anna Rita Vento, Mario Ciocca, Paolo Veronesi, Guillermo Bassani, Gabriela Rosali Dos Santos, Julia Rodriguez, Alberto Luini, Roberto Orecchia, Umberto Veronesi.   

Abstract

AIMS AND
BACKGROUND: Women who have received radiotherapy for Hodgkin's disease have an increased risk of developing breast cancer. Breast-conserving surgery followed by breast irradiation is generally considered to be contraindicated in such patients owing to the high cumulative radiation dose to the breast. Mastectomy is therefore recommended as the preferred treatment option in these women.
METHODS: We report 3 patients affected by breast cancer who had previously been treated with mantle radiation for Hodgkin's disease and on whom breast-conserving surgery and full-dose intraoperative radiotherapy with electrons (ELIOT) were performed.
RESULTS: A total dose of 17 Gy (prescribed at 100% isodose) in one case and 21 Gy (at the 90% isodose) in two cases was delivered directly to the mammary gland without acute complications and with good cosmetic results.
CONCLUSIONS: In women previously irradiated for Hodgkin's disease, ELIOT could avoid repeat irradiation of the whole breast, thereby permitting conservative surgical treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15143964     DOI: 10.1177/030089160409000104

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  2 in total

1.  A new option for early breast cancer patients previously irradiated for Hodgkin's disease: intraoperative radiotherapy with electrons (ELIOT).

Authors:  Mattia Intra; Oreste Gentilini; Paolo Veronesi; Mario Ciocca; Alberto Luini; Roberta Lazzari; Javier Soteldo; Gabriel Farante; Roberto Orecchia; Umberto Veronesi
Journal:  Breast Cancer Res       Date:  2005-08-16       Impact factor: 6.466

2.  Intraoperative radiotherapy (IORT) is an option for patients with localized breast recurrences after previous external-beam radiotherapy.

Authors:  Uta Kraus-Tiefenbacher; Lelia Bauer; Antonella Scheda; Carola Schoeber; Joerg Schaefer; Volker Steil; Frederik Wenz
Journal:  BMC Cancer       Date:  2007-09-14       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.